The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS 2026 | Overlap between MDS and MPNs: parallel development of targeted agents and shared unmet needs
In this video, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, briefly discusses the biologic and therapeutic overlap between myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), specifically myelofibrosis (MF). Dr Mascarenhas explains that several anemia-targeting agents, including recombinant erythropoietin (EPO), luspatercept, and imetelstat, are being evaluated in both diseases. He also notes that combination therapies have not yet outperformed single-agent hypomethylating agents in MDS or JAK inhibitors in MF. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
